TABLE 3 Biogen Idec Inc. March 31, 2007

Condensed Consolidated Statements of Income - Non-GAAP (in millions, except per share amounts) (unaudited)

Three Months Ended

EARNINGS PER SHARE	March 31,			
	2007		2006	
GAAP earnings per share - Diluted	\$	0.38	\$	0.36
Adjustment to net income (as detailed below)		0.21		0.19
Non-GAAP earnings per share - Diluted	\$	0.59	\$	0.55
An itemized reconciliation between net income on a GAAP basis and net income on a non-GAAP basis is as follows:				
GAAP net income	\$	131.5	\$	123.0
Adjustments:				
COGS: Fair value step up of inventory acquired from former Biogen, Inc.		-		4.0
R&D: Stock option expense		3.0		4.8
SG&A: Severance and restructuring		0.1		0.7
SG&A: Stock option expense		6.1		8.3
Amortization of acquired intangible assets related to the merger with former Biogen, Inc., and the				
acquisitions of Conforma Therapeutics Corporation, Fumapharm AG and Syntonix Pharmaceuticals Inc.		59.9		70.7
In-process research and development related to the acquisition of Syntonix Pharmaceuticals Inc.		18.4		-
Gain on sale of long lived assets		-		(0.3)
Income taxes: Income tax effect of reconciling items		(16.6)		(18.4)
Cumulative effect of accounting change from adoption of FAS123R, net of income tax		-		(3.8)
Non-GAAP net income	\$	202.4	\$	188.9

Numbers may not foot due to rounding.